Innoviva Provides Armata Pharmaceuticals with $25M Secured Loan at 14% Interest

summarizeSummary

Armata Pharmaceuticals secured a $25 million high-interest, secured loan from its majority shareholder, Innoviva, Inc., providing essential capital but under costly terms.

check_boxKey Events

• Secured Term Loan Received

  Armata Pharmaceuticals, Inc. borrowed $25,000,000 from Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of its majority shareholder, Innoviva, Inc.

• High Interest Rate

  The secured term loan carries a high annual interest rate of 14.00% and matures on January 11, 2029.

• Majority Shareholder Support

  Innoviva, Inc. and its subsidiary collectively maintain beneficial ownership of approximately 82.7% of Armata's common stock, including shares from existing convertible debt and warrants.

• 15th Schedule 13D Amendment

  This filing is the 15th amendment to Innoviva's Schedule 13D, reflecting the new debt and ongoing financial relationship.

auto_awesomeAnalysis

Innoviva, Inc., the majority shareholder of Armata Pharmaceuticals, has provided a $25 million secured term loan. While this infusion of capital provides crucial liquidity and extends Armata's operational runway, the 14.00% annual interest rate is notably high, suggesting the company faced challenges securing financing on more favorable terms. This transaction reinforces Innoviva's deep involvement and control over Armata's financial structure, as they already beneficially own 82.7% of the company's stock, including existing convertible debt and warrants.